ClinicalTrials.gg
RecruitingNCT06692751EYE-NOCAUpdated Oct 22, 2026

The Value of Measuring Retinal Vascular Density by Optical Coherence Tomography-Angiography (OCT-A) in Patients With Microvascular Angina Confirmed by Myocardial Microcirculatory Resistance Index (MRI).

An observational study in Microvascular Angina, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 22, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
52
Ages
18 Years and older
Sex
All
01

Study summary

Microvascular angina is thought to affect around 112 million patients worldwide. However, this figure is underestimated due to the difficulty of making the diagnosis. It is a pathology caused by an alteration in the microcirculation of the heart muscle, which is not detectable on a standard coronary angiogram.

In view of its prognostic, therapeutic and medico-economic value, scientific societies currently recommend invasive measurement of the microcirculatory resistance index (MRI) to diagnose microvascular angina, in the absence of significant lesions on coronary angiography.

Several research teams, including our own, have shown that cardiovascular risk is associated with alterations in the vascularization of the small vessels (microcirculation) of the retina. Unlike the study of cardiac vessels, the study of retinal microcirculation using fundus photography (OCT-A) is simple, rapid, non-invasive and inexpensive. It appears to be an interesting alternative to the measurement of IMR for the diagnosis of microvascular angina.

This hypothesis has never yet been tested. The demonstration of an association between a decrease in retinal vascular density measured by OCT-A and an alteration in coronary microvascular function measured by IMR would pave the way for a completely non-invasive diagnosis of patients.

This is an observational, cohort, prospective, single-center pilot study comparing people who have received an IMR measurement as part of INOCA.

It is planned to include 158 participants. The overall follow-up period for each patient in the research is 12 months.

In routine care, IMR is measured during coronary angiography in patients presenting with ischemia on a non-invasive test and/or stress symptoms such as angina or dyspnea, for whom coronary angiography does not reveal any significant epicardial lesion.

Following this examination, two groups will be formed: a group with an IMR\<25 and a group with an IMR≥25. Clinically, the study aims to determine the potential role of retinal OCT-A as a non-invasive examination for the diagnosis and/or follow-up of INOCA.

02

Conditions studied

  • Microvascular Angina

Browse trials for

03

In context

Microvascular Angina

111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.

This study's planned enrollment of 52 is below the median of 200 across 46 observational studies indexed under Microvascular Angina.

Browse Microvascular Angina studies →

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 499 studies on the registry; 103 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated at Dijon University Hospital, who received an IMR measurement as part of INOCA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients managed at Dijon University Hospital, having had an IMR measurement as part of INOCA during a coronary angiographic examination, consecutively includible, without angiographically or functionally significant coronary epicardial lesion (FFR \< 0.80) explaining the clinical picture (= INOCA)
  • Person having given oral consent
  • Adult

Exclusion criteria

Exclusion Criteria:

  • Person not affiliated or not benefiting from a social security scheme
  • Person subject to a legal protection measure (curatorship, guardianship) or a safeguard of justice measure
  • Pregnant or breast-feeding women
  • An adult incapable or unable to give consent
  • Person with macular or retinal pathology, or severe bilateral myopia
  • Person with genetic or idiopathic cardiomyopathy (dilated, hypertrophic or restrictive cardiomyopathy)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
52 participants (estimated)
Patient registry
No

Groups and cohorts

  • IMR<25

    People without microvascular angina

    Biological: Blood sampling · Procedure: Ophthalmological examination · Other: angina severity questionnaire

  • IMR≥25

    People with microvascular angina

    Biological: Blood sampling · Procedure: Ophthalmological examination · Other: angina severity questionnaire

Interventions

  • BiologicalBlood sampling

    2 tubes of 5 mL

  • ProcedureOphthalmological examination

    angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation. An optional 20-30 minute WLR may be offered following OCT-A.

  • Otherangina severity questionnaire

    at inclusion, 3 months and 1 year Estimated filling time: 2 minutes

06

What researchers measure

Primary outcomes

  1. Retinal vascular density by "inner vessel length density" determined by OCT-A

    Time frame: At baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2024 (actual). Primary completion is estimated for Nov 2029, 60 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Nov 2027 → Nov 2029 and completion Nov 2027 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 18, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Nov 2029was Nov 2027
CompletionEst.
Nov 2029was Nov 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2027→Nov 2029
Oct 22, 2026
Study completion
Nov 2027→Nov 2029
Oct 22, 2026
Enrollment
158→52
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Nov 2027→Nov 2029
    Study completion Nov 2027→Nov 2029
    Enrollment 158→52
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06692751
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Nov 13, 2024
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Pierre GUILLEMINOT
Contact
pierre.guilleminot@chu-dijon.fr
0380293031

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion